Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KIN's Cash to Debt is ranked higher than
85% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. KIN: No Debt )
KIN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
KIN's Interest Coverage is ranked higher than
92% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
KIN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 29.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -31.17
KIN's ROE (%) is ranked higher than
75% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. KIN: -31.17 )
KIN' s 10-Year ROE (%) Range
Min: -33.44   Max: -13.34
Current: -31.17

-33.44
-13.34
ROA (%) -30.23
KIN's ROA (%) is ranked higher than
73% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. KIN: -30.23 )
KIN' s 10-Year ROA (%) Range
Min: -32.42   Max: -12.68
Current: -30.23

-32.42
-12.68
ROC (Joel Greenblatt) (%) -18497.28
KIN's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. KIN: -18497.28 )
KIN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70316.67   Max: -13415.27
Current: -18497.28

-70316.67
-13415.27
» KIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KIN Guru Trades in Q1 2014

Steven Cohen 15,790 sh (New)
Seth Klarman 2,900,000 sh (New)
Seth Klarman 2,763,848 sh (-4.69%)
» More
Q2 2014

KIN Guru Trades in Q2 2014

Seth Klarman 2,763,848 sh (unchged)
» More
Q3 2014

KIN Guru Trades in Q3 2014

Seth Klarman 3,013,848 sh (+9.05%)
» More
Q4 2014

KIN Guru Trades in Q4 2014

John Rogers 134,425 sh (New)
Jim Simons 20,400 sh (New)
Seth Klarman 3,013,848 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.50
KIN's P/B is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. KIN: 1.50 )
KIN' s 10-Year P/B Range
Min: 0   Max: 5.6
Current: 1.5

0
5.6
EV-to-EBIT -1.51
KIN's EV-to-EBIT is ranked higher than
51% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KIN: -1.51 )
KIN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.51

Current Ratio 35.59
KIN's Current Ratio is ranked higher than
98% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. KIN: 35.59 )
KIN' s 10-Year Current Ratio Range
Min: 13.4   Max: 35.59
Current: 35.59

13.4
35.59
Quick Ratio 35.59
KIN's Quick Ratio is ranked higher than
99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. KIN: 35.59 )
KIN' s 10-Year Quick Ratio Range
Min: 13.4   Max: 35.59
Current: 35.59

13.4
35.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.30
KIN's Price/Net Cash is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. KIN: 1.30 )
KIN' s 10-Year Price/Net Cash Range
Min: 1.5   Max: 2.67
Current: 1.3

1.5
2.67
Price/Net Current Asset Value 1.30
KIN's Price/Net Current Asset Value is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. KIN: 1.30 )
KIN' s 10-Year Price/Net Current Asset Value Range
Min: 1.49   Max: 2.66
Current: 1.3

1.49
2.66
Price/Tangible Book 1.30
KIN's Price/Tangible Book is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. KIN: 1.30 )
KIN' s 10-Year Price/Tangible Book Range
Min: 1.74   Max: 5.15
Current: 1.3

1.74
5.15
Earnings Yield (Greenblatt) -71.10
KIN's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. KIN: -71.10 )
KIN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -131.6   Max: 0
Current: -71.1

-131.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:17K.Germany,
» More Articles for KIN

Headlines

Articles On GuruFocus.com
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 24 2015
KINDRED BIOSCIENCES, INC. Financials Mar 20 2015
Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit Mar 19 2015
Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of... Mar 16 2015
KINDRED BIOSCIENCES, INC. Files SEC form 10-K, Annual Report Mar 13 2015
Kindred Bio reports 4Q loss Mar 12 2015
Kindred Bio reports 4Q loss Mar 12 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 12 2015
Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results Mar 12 2015
KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results Mar 03 2015
Kindred Biosciences (KIN): Strong Industry, Solid Earnings Estimate Revisions Dec 10 2014
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% Dec 08 2014
MId-Day Losers From December 4: Kindred Biosciences, Barnes & Noble, Aeropostale Dec 04 2014
US STOCKS-Volatile energy shares lead Wall St lower after ECB Dec 04 2014
US STOCKS-Wall St falls at open on ECB comments Dec 04 2014
US STOCKS-Futures tick up ahead of ECB, data; Dow eyes 18,000 Dec 04 2014
Kindred Bio stops developing canine atopic dermatitis drug Dec 03 2014
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 03 2014
KindredBio Announces Update on AtoKin and Atopic Dermatitis Program Dec 03 2014
KindredBio to Present at Jefferies 2014 Global London Healthcare Conference Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK